Inventiva S.A. (IVA.PA)
EUR 2.15
(2.38%)
EUR 2.15
(2.38%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 25.61 Million EUR | -10.63% |
| 2022 | 28.66 Million EUR | 224.35% |
| 2021 | 8.83 Million EUR | -11.96% |
| 2020 | 10.03 Million EUR | 501800.0% |
| 2019 | 2000.00 EUR | -97.3% |
| 2018 | 74 Thousand EUR | -66.35% |
| 2017 | 219.93 Thousand EUR | -54.36% |
| 2016 | 481.85 Thousand EUR | -4.39% |
| 2015 | 503.99 Thousand EUR | 1002.47% |
| 2014 | 45.71 Thousand EUR | -54.03% |
| 2013 | 99.44 Thousand EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q4 | 25.61 Million EUR | 0.0% |
| 2023 FY | 25.61 Million EUR | -10.63% |
| 2023 Q2 | 31.01 Million EUR | 0.0% |
| 2022 FY | 28.66 Million EUR | 224.35% |
| 2022 Q2 | 13.43 Million EUR | 0.0% |
| 2022 Q4 | 28.66 Million EUR | 0.0% |
| 2021 FY | 8.83 Million EUR | -11.96% |
| 2021 Q1 | 10.07 Million EUR | 0.38% |
| 2021 Q2 | 10.07 Million EUR | 0.03% |
| 2021 Q4 | 8.74 Million EUR | 0.0% |
| 2020 FY | 10.03 Million EUR | 501800.0% |
| 2020 Q2 | - EUR | 0.0% |
| 2020 Q4 | 10.03 Million EUR | 0.0% |
| 2019 Q4 | 2000.00 EUR | 0.0% |
| 2019 FY | 2000.00 EUR | -97.3% |
| 2019 Q2 | 23 Thousand EUR | 0.0% |
| 2018 Q4 | 74 Thousand EUR | 0.0% |
| 2018 FY | 74 Thousand EUR | -66.35% |
| 2018 Q2 | 147.08 Thousand EUR | 0.0% |
| 2017 FY | 219.93 Thousand EUR | -54.36% |
| 2017 Q4 | 219.93 Thousand EUR | 0.0% |
| 2017 Q2 | 403.99 Thousand EUR | 0.0% |
| 2016 Q4 | 481.85 Thousand EUR | 0.0% |
| 2016 FY | 481.85 Thousand EUR | -4.39% |
| 2016 Q2 | 550.43 Thousand EUR | 0.0% |
| 2015 FY | 503.99 Thousand EUR | 1002.47% |
| 2015 Q4 | 503.99 Thousand EUR | 0.0% |
| 2014 FY | 45.71 Thousand EUR | -54.03% |
| 2013 FY | 99.44 Thousand EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -2226.612% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 42.69% |
| Adocia SA | 4.54 Million EUR | -464.229% |
| Aelis Farma SA | 2.04 Million EUR | -1150.781% |
| Biophytis S.A. | 3.11 Million EUR | -723.401% |
| Advicenne S.A. | 15.89 Million EUR | -61.147% |
| genOway Société anonyme | 5.51 Million EUR | -364.117% |
| IntegraGen SA | 642.28 Thousand EUR | -3888.292% |
| Medesis Pharma S.A. | 1.2 Million EUR | -2034.667% |
| Neovacs S.A. | 650 Thousand EUR | -3840.923% |
| NFL Biosciences SA | 39.2 Thousand EUR | -65241.938% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -487.994% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -1206.719% |
| Sensorion SA | 1.24 Million EUR | -1964.29% |
| Theranexus Société Anonyme | 2.46 Million EUR | -940.997% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -557.158% |
| TheraVet SA | 1 Million EUR | -2460.067% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | -270.924% |
| argenx SE | 15.35 Million EUR | -66.836% |
| BioSenic S.A. | 15.57 Million EUR | -64.49% |
| Celyad Oncology SA | 902 Thousand EUR | -2739.911% |
| DBV Technologies S.A. | 4.52 Million USD | -465.974% |
| Galapagos NV | 4.94 Million EUR | -418.123% |
| Genfit S.A. | 62.25 Million EUR | 58.852% |
| GeNeuro SA | 6.49 Million EUR | -294.56% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -7346.512% |
| Innate Pharma S.A. | 30.6 Million EUR | 16.307% |
| MaaT Pharma SA | 5.42 Million EUR | -372.184% |
| MedinCell S.A. | 52.8 Million EUR | 51.485% |
| Nanobiotix S.A. | 41.66 Million EUR | 38.512% |
| Onward Medical N.V. | 16.3 Million EUR | -57.096% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -642.36% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 27.859% |
| Oxurion NV | 117 Thousand EUR | -21794.017% |
| Pharming Group N.V. | 123.65 Million EUR | 79.285% |
| Poxel S.A. | 40.14 Million EUR | 36.188% |
| GenSight Biologics S.A. | 1.04 Million EUR | -2344.275% |
| Transgene SA | 17 Thousand EUR | -150582.353% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.11% |
| Valneva SE | 132.76 Million EUR | 80.706% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |